



# Kansas State Board of Pharmacy

Landon State Office Bldg  
900 Jackson, Room 560  
Topeka, KS 66612  
[www.accesskansas.org/pharmacy](http://www.accesskansas.org/pharmacy)

Published to promote voluntary compliance of pharmacy and drug law.

## Board Honors 50-year Pharmacists

Congratulations to the following pharmacists who have been licensed in good standing with the Kansas State Board of Pharmacy for 50 years. The Board of Pharmacy is grateful for their years of contribution to the pharmacy profession.

- Haven L. Kelley ..... Wichita
- Gerald A. Bales ..... Wellington
- John J. Witmer ..... Phillipsburg
- Norton K. Turner ..... Wichita
- Robert E. Seutter ..... Lee's Summit
- Douglas T. Margreiter ..... Denver
- Charles W. Wright ..... Winfield

## Disciplinary Actions

**David D. Vanhoozier** – Carrollton, TX, has entered into a consent agreement whereby he has surrendered his license based on unprofessional conduct.

**Louie A. Ferro, Jr** – Independence, MO, has been revoked. Ferro Jr pled guilty to 22 felony counts of Medicaid fraud in violation of K.S.A. 65-1627(2).

**Valjean Van Winkle** – was disciplined by the Board by being placed on probation for five years subject to conditions.

## DEA to Issue Unique DEA Number

The Board of Pharmacy was notified by Drug Enforcement Administration (DEA) that pharmacists would now play a role in the delivery of opiate addiction treatment. Suboxone® and Subutex® are sublingual tablets indicated for the treatment of opioid dependence. These are the first medications approved for office-based treatment of opioid dependence under the Drug Addiction Treatment Act of 2000 (DATA). Prior to the passage of this law, it was illegal for a doctor to prescribe narcotic drugs for the treatment of narcotic dependence. Opioid dependence treatment of this type could only be provided at specially registered clinics. Under the new law, only opiate addiction treatment drugs under Schedule II are confined to use in the clinic setting. Less tightly controlled drugs (Schedule III-V) may be prescribed for

opiate addiction treatment by specially qualified doctors who treat patients in their private offices.

Suboxone and Subutex are controlled as Schedule III narcotics under the Controlled Substances Act. The DATA limits office-based use of Suboxone and Subutex to physicians who meet special training criteria and can provide appropriate services. To be qualified, physicians must:

- Meet one or more of the following training requirements:
  - ◆ Hold a subspecialty board certification in addiction psychiatry from the American Board of Medical Specialties;
  - ◆ Hold a subspecialty board certification in addiction medicine from the American Osteopathic Association;
  - ◆ Hold an addiction certification from the American Society of Addiction Medicine; or
  - ◆ Have completed not less than eight hours of authorized training on the treatment or management of opioid-dependent patients. This training may include classroom situations, seminars at professional society meetings, electronic communications, or other media. The American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association are all authorized to provide this training.
- And meet both of the following criteria:
  - ◆ Have the capacity to provide or to refer patients for necessary ancillary services, such as psycho-social therapy; and
  - ◆ Agree to treat no more than 30 patients at any one time in their individual or group practice.

Physicians who meet the qualification criteria listed above must also notify the secretary of the United States Department of Health and Human Services (DHHS) of their intent to prescribe Suboxone and Subutex before doing so. Once

*Continued on page 4*

Continued from page 1

all relevant criteria are verified, DEA will issue the physician a unique identification number indicating that he or she is a qualifying physician under DATA. The Center for Substance Abuse Treatment (CSAT, a component of the Substance Abuse and Mental Health Services Administration – SAMHSA) will send a letter informing the physician of the new DEA identification number. The physician will subsequently receive a revised DEA registration certificate (showing both numbers). Pharmacists who seek information to verify whether or not physicians have valid waivers may call 1-866/BUP-CSAT or e-mail [info@buprenorphine.samhsa.gov](mailto:info@buprenorphine.samhsa.gov).

Call the physician for clarification that the physician has made the appropriate notification to DHHS. DEA is developing regulations that will require this number along with the physician's existing DEA registration number to be included on all prescriptions issued for the treatment of opioid dependence; therefore, physicians are being strongly urged to include this number on prescriptions.

Most physicians will make arrangements to obtain the identification number before prescribing Suboxone or Subutex, but in rare cases a physician may need to write a prescription before the number has been issued. This is allowed under the DATA provided the physician has notified the DHHS of his/her intention to begin treating a patient right away; the notification form includes a check box for this situation.

Doctors in each state who have waivers to prescribe buprenorphine for the treatment of opioid addiction are listed on the SAMHSA Buprenorphine Physician Locator Web site at: [www.buprenorphine.samhsa.gov/bwns\\_locator/index.html](http://www.buprenorphine.samhsa.gov/bwns_locator/index.html).

## License Renewal

Pharmacist license renewals for licenses ending in an even number will be sent out in May 2004. Continuing education credits need to be dated June 1, 2002, or after, and must be Accreditation Council for Pharmacy Education approved. You may renew online. Take advantage of this convenient way to renew.

## Board Meeting Dates

The next Kansas State Board of Pharmacy meeting has been scheduled for June 9-10, 2004. The meeting will be held at the AmeriSuites conference room located at 6021 SW 6<sup>th</sup> in Topeka, KS. September 21-22, 2004, is the date of the fall meeting. The Board meeting agenda is listed on the Board's Web site at [www.accesskansas.org/pharmacy](http://www.accesskansas.org/pharmacy). If you wish to receive notice of Board meetings, please e-mail the Board office at [pharmacy@pharmacy.state.ks.us](mailto:pharmacy@pharmacy.state.ks.us).

---

Page 4 – March 2004

The *Kansas State Board of Pharmacy News* is published by the Kansas State Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote voluntary compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of the Foundation or the Board unless expressly so stated.

Debra L. Billingsley, BS, JD - State News Editor  
Carmen A. Catizone, MS, RPh, DPh - National News Editor  
& Executive Editor  
Reneeta C. "Rene" Renganathan - Editorial Manager

Presorted Standard  
U.S. Postage  
PAID  
Chicago, Illinois  
Permit No. 5744

National Association of Boards of Pharmacy Foundation, Inc  
700 Busse Highway  
Park Ridge, Illinois 60068  
KANSAS STATE BOARD OF PHARMACY